Withdrawal confounding in randomized controlled trials of antipsychotic, antidepressant, and stimulant drugs, 2000-2017
The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
Background: Results of relapse prevention randomized controlled trials (RCTs) which discontinue psychotropic drug treatment from some participants may be confounded by drug withdrawal symptoms. We test for the confound by calculating whether ≥50% of the difference in relapse risk between drug-discontinued and drug-maintained groups is present at discontinuation time points (DCTs) with “short” and “long” assumptions regarding onset and duration of withdrawal symptoms. Methods: In eligible RCTs of antidepressants, antipsychotics, and stimulants from 2000 to 2017 (n = 30) selected from a systematic review, differences in relapse risk were examined by arithmetic and graphical comparison of mean behavioral scores or survival plots. Results: Only 14 studies (46.6%) with 15 analyses of relapse risk provided sufficient data. Under short and long DCTs, 9 of 13 (69.2%) and 7 of 9 (77.8%) interpretable analyses, respectively, suggested a withdrawal confound. The proportion of endpoint placebo-maintenance group difference present by the DCT averaged 69.1% (range, 58.7–148.0%, n = 13) for short DCT assumptions, and 79.0% (range, 51.5–183.3%, n = 9) under long DCTs. One study (3.33%) controlled for withdraw al effects, and 1 yielded inconclusive results. Conclusions: These results support suggestions that withdrawal symptoms confound the results of relapse prevention RCTs. Accounting for such symptoms in RCTs is an ethical, scientific, and clinical imperative. Justifications for relapse prevention RCTs employing a discontinuation procedure require more scrutiny.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“although none of the trials on which this conclusion was based measured withdrawal effects (Cohen 2019;Hengartner 2020;Recalt 2019)”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Recalt 2019
In the citing paper
“Current diagnostic methods in psychiatry, both DSM-5 [182] and ICD-11 [205], are inadequate to assess psychotropic medication withdrawal because they do not take into account the issue of iatrogenic comorbidity [28] and they refer to drug-free patients, although most of the psychiatric cases seen at first visit in psychiatry and in clinical psychology are already under a psychotropic medication [”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [182]
In the citing paper
“However, in these studies, withdrawal effects from the rapid discontinuation of antidepressants are ignored, inflating the apparent rate of relapse recorded in this group, therefore exaggerating the perceived ‘relapse prevention’ properties of antidepressants.20,41”
In the citing paper
“The evidence supporting this strategy, however, is based mainly on clinical trials where remitted patients were randomized to drug continuation or placebo, without any differentiation between withdrawal and relapse.”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [67]
In the citing paper
“we have no way to know how many of the relapses were actually withdrawal and post-withdrawal syndromes in the group that underwent drug tapering and discontinuation.”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [67]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Understanding and misunderstanding randomized controlled trials
Deaton, A., & Cartwright, N. (2018) · Social Science & Medicine · doi:10.1016/j.socscimed.2017.12.005 · Cited by 1,841
Temple, R., & Ellenberg, S. S. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-6-200009190-00014 · Cited by 871
Prien, R. F. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790220086014 · Cited by 565
Goodwin, G. M., Emsley, R., Rembry, S., Rouillon, F., & the Agomelatine Study Group (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04548 · Cited by 340
Research Units on Pediatric Psychopharmacology Autism Network (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1361 · Cited by 288
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000477313 · Cited by 270
The case for practical clinical trials in psychiatry.
March, J. S., Silva, S. G., Compton, S., Shapiro, M., Califf, R., & Krishnan, R. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.5.836 · Cited by 240
Troost, P. W., Lahuis, B. E., Steenhuis, M.-P., Ketelaars, C. E. J., Buitelaar, J. K., van Engeland, H., Scahill, L., Minderaa, R. B., & Hoekstra, P. J. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000177055.11229.76 · Cited by 203
Neuroleptic Withdrawal in Schizophrenic Patients
Baldessarini, R. J. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150021002 · Cited by 195
Cited by
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
Van Leeuwen, E., van Driel, M. L., Horowitz, M. A., Kendrick, T., Donald, M., De Sutter, A. I., Robertson, L., & Christiaens, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013495.pub2 · Cited by 90
Fava, G. A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320970325 · Cited by 84
Iatrogenic Factors in Psychopathology
Fava, G. A., & Rafanelli, C. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000500151 · Cited by 82
Guy, A., Brown, M., Lewis, S., & Horowitz, M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320967183 · Cited by 77
Metadata
- Authors
- Récalt, A. M., & Cohen, D.
- Affiliations
- University of California, Los Angeles (US)
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2019
- Volume
- 88
- Issue
- 2
- Pages
- 105-113
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2925187958
- Semantic Scholar
- be6b7f967298e5b5d8cbdc38e2a169c5341688ec
- Cited by
- 38
- References
- 37
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 4 · 2023: 4 · 2022: 3 · 2021: 11 · 2020: 9 · 2019: 2
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Keywords
- drug withdrawal symptoms, confounding, relapse prevention, psychotropic drugs, antipsychotic drugs, antidepressants, stimulants, drug discontinuation, relapse risk, randomized controlled trials
- MeSH terms
- Central Nervous System Stimulants, Antidepressive Agents, Humans, Substance Withdrawal Syndrome, Antipsychotic Agents, Randomized Controlled Trials as Topic, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Withdrawal confounding in randomized controlled trials of antipsychotic, antidepressant, and stimulant drugs, 2000-2017. https://app.cochat.ai/papers/10.1159/000496734
- The paper
- Récalt, A. M., & Cohen, D. (2019). Withdrawal confounding in randomized controlled trials of antipsychotic, antidepressant, and stimulant drugs, 2000-2017. Psychotherapy and Psychosomatics. https://doi.org/10.1159/000496734
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.